This article is more than 5 years old. Information may no longer be current.

WaveLight achieves 20% of U.S. refractive laser sales

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

NEW ORLEANS — In its first year in the American market, WaveLight Inc. achieved a 20% share of all new U.S. refractive laser sales, according to independent market analyst Market Scope. WaveLight announced the finding during the American Academy of Ophthalmology meeting here.

“Despite a late start in the U.S. market, WaveLight has captured a significant share of new laser sales during the past year,” said David Harmon, president of Market Scope, in a press release from WaveLight.

The WaveLight Allegretto Wave excimer laser system gained Food and Drug Administration approval in October 2003.

The company also announced that it received an investigational device exemption from the FDA in September to conduct further U.S. clinical studies with its laser, including trials with expanded treatment ranges and wavefront-guided LASIK.

WaveLight has been the leader in new refractive laser sales internationally for 2 years in a row, the company said.